BUSINESS COMBINATION AND DECONSOLIDATION OF SUBSIDIARY (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	May 14, 2019	Apr. 15, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Preliminary purchase price					$ 34,069,942
Acquisition costs					399,942
General and administrative expenses					$ 290,209
Total potential shares to be issued					32,072,283
Contingent consideration liability			$ 14,632,000		$ 14,632,000
Gain on deconsolidation			$ 80,868		$ 80,868
Termination And Release Agreement [Member] | Oak Therapeutics [Member]
Gain on deconsolidation		$ 80,868
Minimum [Member]
Estimated useful lives of identifiable finite-lived intangible assets					11 years
Maximum [Member]
Estimated useful lives of identifiable finite-lived intangible assets					14 years
Merger Agreement [Member]
Contingent shares					26,372,283
Convertible Note [Member]
Debt instrument converted amount, principal	$ 2,000,000
Monte-Carlo simulation Model [Member]
Preliminary purchase price description					The preliminary total purchase price was determined based on the following: i) Company’s closing price ($3.34) on May 14, 2019 for the Upfront Consideration Share; ii) the estimated fair value using the Monte-Carlo simulation of stock price correlation, and other variables over a 66 month performance period applied to the total number of contingent shares, which consists of the Clawback Shares, Achievement Shares and Earnout Shares, as determined based on the weighted average present value probability of each the various estimates of milestones, earn-out amounts and achievements being accomplished (“Adjusted Contingent Shares”); iii) the fair value of the Acquisition Warrant Shares based on using the Black-Scholes valuation using the a risk free rate of 2.4%, stock price volatility of 134.7%, no dividend payout, 1 year expected life, exercise price of $5.01 and an estimated stock price of $0.39 based on the end of the earn-out period, year 4 (as determine by using a Monte-Carlo simulation model);
Chemistry Holdings [Member]
Common stock including escrowed shares description	On May 14, 2019, the Company acquired all of the issued and outstanding stock of CHI for shares of the Company’s Common Stock. The maximum number of shares of Common Stock to be issued, including escrowed shares and shares issuable pursuant to a variety of earn-out provisions and warrants, is 32,072,283 shares. The shares are allocated as follows: (i) 5,700,000 shares of Common Stock as upfront consideration issued at the Closing (the “Upfront Consideration Shares”); (ii) 7,128,913 shares to be held in escrow, subject to indemnification and clawback rights that lapse upon the achievement of certain milestones (the “Clawback Shares”); (iii) up to 3,207,228 shares that may be issued pursuant to an earn-out over five years upon the achievement of certain technological implementations (“Achievement Shares”); (iv) up to 8,018,071 shares that may be issued pursuant to an earn-out over two years upon the achievement of certain revenue goals (“Earnout Shares”); and (v) up to 8,018,071 shares issuable upon exercise of warrants (“Acquisition Warrants”) that become exercisable upon achieving certain revenue goals between the second and fourth anniversary of the Closing Date at an exercise price of $5.01 per share, exercisable, to the extent vested, for five years from the Closing Date.